1. Echocardiographic measures associated with the presence of left ventricular thrombus in patients with chemotherapy-related cardiac dysfunction
- Author
-
Song Juhee, Rohit Moudgil, Liza Sanchez, Michele Guindani, Danai Kitkungvan, Nicolas Palaskas, Saamir Hassan, Syed Wamique Yusuf, and Jose Banchs
- Subjects
Male ,medicine.medical_specialty ,Heart Diseases ,medicine.medical_treatment ,Heart Ventricles ,Cardiomyopathy ,Antineoplastic Agents ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Ventricular Dysfunction, Left ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,cardiovascular diseases ,030212 general & internal medicine ,Thrombus ,Not evaluated ,Chemotherapy ,Univariate analysis ,Ejection fraction ,business.industry ,Thrombosis ,Left ventricular thrombus ,Middle Aged ,medicine.disease ,Echocardiography ,cardiovascular system ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,circulatory and respiratory physiology - Abstract
BACKGROUND Previous studies have not evaluated the prevalence and specific risk factors for the development of left ventricular (LV) thrombus in patients with severely reduced left ventricular dysfunction due to chemotherapy-related cardiomyopathy. We sought to evaluate the prevalence and potential markers of LV thrombus in this patient population. METHODS From January 2009 to December 2013, patients with chemotherapy-related severe LV dysfunction (LV ejection fraction [LVEF] ≤ 30%) identified from MD Anderson Cancer Center database were reviewed. Patient characteristics and echocardiographic parameters were analyzed to determine potential risk factors for LV thrombus. RESULTS A total of 121 patients met inclusion criteria (age 54.8 ± 15.2 years; female 63.6%; LVEF 26.3 ± 4%). LV thrombus was present in 9 patients (7.4%). Patients with LV thrombus have significantly lower LVEF compared to those without (18.7 ± 3.8% vs 26.9 ± 3.4%, P
- Published
- 2018